GlassScriptPhysician profile
Davis B Marshall
NPI 1962874883
$8,090.20
in general payments reported to CMS, 2019-2025
31 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $2,349 · 2023: $1,668 · 2024: $1,961 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,244 · Education: $20.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,244.31 |
| Education | $20.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,138.34 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,021.39 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $856.40 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $656.72 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $625.34 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $310.69 | 2021-2024 | Linzess |
| Genzyme Corporation | $256.22 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $231.44 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $180.17 | 2024-2025 | Voquezna |
| Pfizer INC. | $169.10 | 2021-2025 | |
| Lilly USA, LLC | $158.94 | 2023-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $149.48 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $143.56 | 2021-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Daiichi Sankyo INC. | $114.12 | 2023-2025 | Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $110.54 | 2022-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $104.92 | 2022-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $104.43 | 2023-2024 | Idacio |
| Celgene Corporation | $94.96 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $87.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $83.31 | 2022-2024 | Dificid |
| Organon LLC | $67.22 | 2022-2024 | |
| Ardelyx, INC. | $58.02 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $44.88 | 2025 | Wegovy |
| Celltrion USA INC. | $44.22 | 2024 | Vegzelma, Zymfentra |
| Intra-Sana Laboratories | $43.30 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $27.80 | 2025 | Iqirvo |
| Axonics, INC. | $25.20 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $20.55 | 2023 | Monoferric |
| Braintree Laboratories, INC. | $20.32 | 2023 | Sutab |
| Exact Sciences Corporation | $16.30 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davis Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.